News | November 16, 2022
Cadila recognized for its contribution to leprosy treatment
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
The company sees the business reaching $100mn
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults.
The laboratory is equipped to perform high-volume diagnostic testing services
Subscribe To Our Newsletter & Stay Updated
